24.0766:  A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.

Principal Investigator: Rebecca Redman, MD

Phase:  1/1b

Description:  The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.

ClinicalTrials.gov:  https://clinicaltrials.gov/study/NCT05853367?term=NCT05853367&rank=1

24.0590:  A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced endometrial cancer 

Principal Investigator: Jason Chesney, MD, PhD 

Phase:  II 

Description:  The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

 ClinicalTrials.gov:  https://clinicaltrials.gov/study/NCT06481592?term=NCT06481592&rank=1

22.0392:  COMBINATION THERAPY WITH LIPOSOMAL DOXORUBICIN AND WITHAFERIN A (ASHWAGANDHA, ASWD) IN RECCURENT OVARIAN CANCER 

Principal Investigator: Whitney Goldsberry 

Phase:  I 

Description:  This is a two-part open-label clinical trial of ASWD (Ashwagandha) administered to patients with recurrent platinum resistant ovarian cancer in combination with liposomal doxorubicin, following at least two previous lines of chemotherapy. Patients will initially be enrolled in part 1 of the study, which is the feasibility/tolerability evaluation. Once the part 1enrollment is completed, the patients will be enrolled in part 2 of the study. 

More Info:  https://clinicaltrials.gov/study/NCT05610735?term=NCT05610735&rank=1

08.0388 - Protocol for the Cancer Database and Specimen Repository (CDSR) at the Brown Cancer Center (Previous Lung Repository).

Principal Investigator: Rebecca Redman, M.D.

Description: The mission of the Cancer Database and Specimen Repository (CDSR) is to collect clinical information and samples of human specimens from cancer patients and from control patients for research, and to distribute specimens to researchers for the advancement of science.